Skip to main content

Table 5 Univariate and multivariate for factors related to lymph node metastasis in patients with pre-operative biopsy diagnosed ductal carcinoma in situ

From: Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI

  Univariate analysis Multivariate analysis
Odds ratio 95% CI P Odds ratio 95% CI P
Age 0.97 0.94–1 0.06    
Pathologya tumor size (cm) overall group 1.01 0.9–1.13 0.9    
Pathologya DCIS-IC invasive part tumor size (invasive, cm) excluding pure DCIS cases 1.32 1.1–1.59  < 0.01    
MRI tumor size (cm) 1.21 1–1.42 0.02    
Sonogram tumor size (cm) 1.8 1.4–2.3  < 0.01 1.93 1.23–3.03  < 0.01
Mammogram tumor size (cm) 1.78 1–3.09 0.04    
Pathology glossb tumor size ( cm) 1.03 0.91–1.16 0.63    
Pathology-DCIS-IC glosstumor size ( cm) 0.99 0.86–1.13 0.86    
Pathology-pure DCIS glossb tumor size ( cm) 0.54 0.15–1.99 0.36    
Post OP biopsy (IDC) VS DCIS 34.94 10.73–113.79  < 0.01 36.37 4.63–288.81  < 0.01
Grade (II, III)VS I 1.1 0.42–2.88 0.85    
ER (positive) VS negative 0.61 0.33–1.11 0.1    
PR (positive) VS negative 0.7 0.38–1.26 0.23    
HER-2 (positive) VS negative 0.89 0.47–1.68 0.72    
Ki -67 (> 20)VS 20 1.64 0.71–3.81 0.25    
MRI lymph node metastasis (Y)VS N 4.08 1.82–9.18  < 0.01 2.2 0.83–5.83 0.11
  1. MMG mammography guided biopsy, LN lymph node, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, ND not done, OP operation, DCIS ductal carcinoma in situ, TNBC triple negative breast cancer, ER estrogen receptor, PR progesterone receptor, HER-2 human epithelial grow receptor type 2, N/A not available
  2. aPathology tumor size: in pure DCIS cases pathologic tumor size=DCIS tumor size, if containing invasive component then pathologic tumor size=invasive cancer tumor size
  3. bGross tumor size: invasive + non-invasive component tumor size